| 0069-0324 | These highlights do not include all the information needed to use NYVEPRIA safely and effectively. See full prescribing information for NYVEPRIA. NYVEPRIA™ (pegfilgrastim-apgf) injection, for subcutaneous use Initial U.S. Approval: 2020 NYVEPRIA (pegfilgrastim-apgf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe | Pfizer Laboratories Div Pfizer Inc | Hospira Zagreb d.o.o. | Pfizer Inc |
| 0069-0324 | These highlights do not include all the information needed to use NYVEPRIA safely and effectively. See full prescribing information for NYVEPRIA. NYVEPRIA™ (pegfilgrastim-apgf) injection, for subcutaneous use Initial U.S. Approval: 2020 | Pfizer Laboratories Div Pfizer Inc | Hospira Zagreb d.o.o. | Pfizer Inc |
| 0069-0324-01 | These highlights do not include all the information needed to use NYVEPRIA safely and effectively. See full prescribing information for NYVEPRIA. NYVEPRIA™ (pegfilgrastim-apgf) injection, for subcutaneous use Initial U.S. Approval: 2020 NYVEPRIA (pegfilgrastim-apgf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differe | Pfizer Laboratories Div Pfizer Inc | Hospira Zagreb d.o.o. | Pfizer Inc |
| 0069-0324-01 | These highlights do not include all the information needed to use NYVEPRIA safely and effectively. See full prescribing information for NYVEPRIA. NYVEPRIA™ (pegfilgrastim-apgf) injection, for subcutaneous use Initial U.S. Approval: 2020 | Pfizer Laboratories Div Pfizer Inc | Hospira Zagreb d.o.o. | Pfizer Inc |
| 55513-099 | These highlights do not include all the information needed to use NEULASTA safely and effectively. See full prescribing information for NEULASTA. NEULASTA ® (pegfilgrastim) injection, for subcutaneous use Initial U.S. Approval: 2002 | Amgen, Inc | Amgen Manufacturing Limited LLC |
| 55513-099-01 | These highlights do not include all the information needed to use NEULASTA safely and effectively. See full prescribing information for NEULASTA. NEULASTA ® (pegfilgrastim) injection, for subcutaneous use Initial U.S. Approval: 2002 | Amgen, Inc | Amgen Manufacturing Limited LLC |
| 55513-190 | These highlights do not include all the information needed to use NEULASTA safely and effectively. See full prescribing information for NEULASTA. NEULASTA ® (pegfilgrastim) injection, for subcutaneous use Initial U.S. Approval: 2002 | Amgen, Inc | Amgen Manufacturing Limited LLC |
| 55513-190-01 | These highlights do not include all the information needed to use NEULASTA safely and effectively. See full prescribing information for NEULASTA. NEULASTA ® (pegfilgrastim) injection, for subcutaneous use Initial U.S. Approval: 2002 | Amgen, Inc | Amgen Manufacturing Limited LLC |
| 55513-192 | These highlights do not include all the information needed to use NEULASTA safely and effectively. See full prescribing information for NEULASTA. NEULASTA ® (pegfilgrastim) injection, for subcutaneous use Initial U.S. Approval: 2002 | Amgen, Inc | Amgen Manufacturing Limited LLC |
| 55513-192-01 | These highlights do not include all the information needed to use NEULASTA safely and effectively. See full prescribing information for NEULASTA. NEULASTA ® (pegfilgrastim) injection, for subcutaneous use Initial U.S. Approval: 2002 | Amgen, Inc | Amgen Manufacturing Limited LLC |
| 61314-866 | These highlights do not include all the information needed to use ZIEXTENZO safely and effectively. See full prescribing information for ZIEXTENZO. ZIEXTENZO ® (pegfilgrastim-bmez) injection, for subcutaneous use Initial U.S. Approval: 2019 ZIEXTENZO (pegfilgrastim-bmez) is biosimilar* to NEULASTA ® (pegfilgrastim). | Sandoz Inc |
| 61314-866-01 | These highlights do not include all the information needed to use ZIEXTENZO safely and effectively. See full prescribing information for ZIEXTENZO. ZIEXTENZO ® (pegfilgrastim-bmez) injection, for subcutaneous use Initial U.S. Approval: 2019 ZIEXTENZO (pegfilgrastim-bmez) is biosimilar* to NEULASTA ® (pegfilgrastim). | Sandoz Inc |
| 61314-866-02 | These highlights do not include all the information needed to use ZIEXTENZO safely and effectively. See full prescribing information for ZIEXTENZO. ZIEXTENZO ® (pegfilgrastim-bmez) injection, for subcutaneous use Initial U.S. Approval: 2019 ZIEXTENZO (pegfilgrastim-bmez) is biosimilar* to NEULASTA ® (pegfilgrastim). | Sandoz Inc |
| 65219-371 | These highlights do not include all the information needed to use STIMUFEND safely and effectively. See full prescribing information for STIMUFEND. STIMUFEND ® (pegfilgrastim-fpgk) injection, for subcutaneous use Initial U.S. Approval: 2022 STIMUFEND (pegfilgrastim-fpgk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful di | Fresenius Kabi USA, LLC | Merck Biodevelopment, Martillac | FUJIFILM Diosynth Biotechnologies UK Ltd. | Merck Serono S.p.A (MS-Bari) | Merck Serono S.p.A (MS-Guidonia) | Istituto di Ricerche Biomediche Antoine marxer RBM S.P.A | Fresenius Kabi Austria GmbH |
| 65219-371-10 | These highlights do not include all the information needed to use STIMUFEND safely and effectively. See full prescribing information for STIMUFEND. STIMUFEND ® (pegfilgrastim-fpgk) injection, for subcutaneous use Initial U.S. Approval: 2022 STIMUFEND (pegfilgrastim-fpgk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful di | Fresenius Kabi USA, LLC | Merck Biodevelopment, Martillac | FUJIFILM Diosynth Biotechnologies UK Ltd. | Merck Serono S.p.A (MS-Bari) | Merck Serono S.p.A (MS-Guidonia) | Istituto di Ricerche Biomediche Antoine marxer RBM S.P.A | Fresenius Kabi Austria GmbH |
| 67457-833 | These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for FULPHILA. FULPHILA ® (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2018 FULPHILA ® (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). (1) | Mylan Institutional LLC |
| 67457-833-06 | These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for FULPHILA. FULPHILA ® (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2018 FULPHILA ® (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). (1) | Mylan Institutional LLC |
| 69448-025 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Accord BioPharma, Inc. |
| 69448-025-63 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Accord BioPharma, Inc. |
| 69448-026 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Accord BioPharma, Inc. |
| 69448-026-63 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Accord BioPharma, Inc. |
| 69448-027 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Accord BioPharma, Inc. |
| 69448-027-63 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Accord BioPharma, Inc. |
| 70114-101 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Coherus Oncology, Inc. |
| 70114-101-01 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Coherus Oncology, Inc. |
| 70114-120 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Coherus Oncology, Inc. |
| 70114-120-01 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Coherus Oncology, Inc. |
| 70114-130 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Coherus Oncology, Inc. |
| 70114-130-01 | These highlights do not include all the information needed to use UDENYCA safely and effectively. See full prescribing information for UDENYCA. UDENYCA ® (pegfilgrastim-cbqv) injection, for subcutaneous use INITIAL U.S. APPROVAL: 2018 UDENYCA (pegfilgrastim-cbqv) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful difference | Coherus Oncology, Inc. |
| 70121-1627 | These highlights do not include all the information needed to use FYLNETRA safely and effectively. See full prescribing information for FYLNETRA . FYLNETRA ® (pegfilgrastim-pbbk ) injection, for subcutaneous use Initial U.S. Approval: 2022 FYLNETRA (pegfilgrastim-pbbk) is biosimilar* to NEULASTA (pegfilgrastim). | Amneal Pharmaceuticals LLC | Kashiv BioSciences, LLC |
| 70121-1627-1 | These highlights do not include all the information needed to use FYLNETRA safely and effectively. See full prescribing information for FYLNETRA . FYLNETRA ® (pegfilgrastim-pbbk ) injection, for subcutaneous use Initial U.S. Approval: 2022 FYLNETRA (pegfilgrastim-pbbk) is biosimilar* to NEULASTA (pegfilgrastim). | Amneal Pharmaceuticals LLC | Kashiv BioSciences, LLC |
| 70748-273 | These highlights do not include all the information needed to use ARMLUPEG safely and effectively. See full prescribing information for ARMLUPEG. ARMLUPEG (pegfilgrastim-unne) injection, for subcutaneous use Initial U.S. Approval: 2025 ARMLUPEG (pegfilgrastim-unne) is biosimilar* to NEULASTA (pegfilgrastim) (1) | Lupin Pharmaceuticals, Inc. | Lupin Limited |
| 70748-273-01 | These highlights do not include all the information needed to use ARMLUPEG safely and effectively. See full prescribing information for ARMLUPEG. ARMLUPEG (pegfilgrastim-unne) injection, for subcutaneous use Initial U.S. Approval: 2025 ARMLUPEG (pegfilgrastim-unne) is biosimilar* to NEULASTA (pegfilgrastim) (1) | Lupin Pharmaceuticals, Inc. | Lupin Limited |
| 72603-402 | These highlights do not include all the information needed to use STIMUFEND safely and effectively. See full prescribing information for STIMUFEND. STIMUFEND ® (pegfilgrastim-fpgk) injection, for subcutaneous use Initial U.S. Approval: 2022 STIMUFEND (pegfilgrastim-fpgk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful di | NORTHSTAR RX LLC | Merck Biodevelopment, Martillac | FUJIFILM Diosynth Biotechnologies UK Ltd. | Merck Serono S.p.A (MS-Bari) | Merck Serono S.p.A (MS-Guidonia) | Istituto di Ricerche Biomediche Antoine marxer RBM S.P.A | Fresenius Kabi USA, LLC | Fresenius Kabi Austria GmbH |
| 72603-402-01 | These highlights do not include all the information needed to use STIMUFEND safely and effectively. See full prescribing information for STIMUFEND. STIMUFEND ® (pegfilgrastim-fpgk) injection, for subcutaneous use Initial U.S. Approval: 2022 STIMUFEND (pegfilgrastim-fpgk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful di | NORTHSTAR RX LLC | Merck Biodevelopment, Martillac | FUJIFILM Diosynth Biotechnologies UK Ltd. | Merck Serono S.p.A (MS-Bari) | Merck Serono S.p.A (MS-Guidonia) | Istituto di Ricerche Biomediche Antoine marxer RBM S.P.A | Fresenius Kabi USA, LLC | Fresenius Kabi Austria GmbH |
| 83257-005 | These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for FULPHILA. FULPHILA TM (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2018 FULPHILA TM (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). (1) | Biocon Biologics Inc. | Biocon Biologics Limited |
| 83257-005 | These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for FULPHILA. FULPHILA ® (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2018 FULPHILA ® (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). (1) | Biocon Biologics Inc. | Biocon Biologics Limited |
| 83257-005-41 | These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for FULPHILA. FULPHILA TM (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2018 FULPHILA TM (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). (1) | Biocon Biologics Inc. | Biocon Biologics Limited |
| 83257-005-41 | These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for FULPHILA. FULPHILA ® (pegfilgrastim-jmdb) injection, for subcutaneous use Initial U.S. Approval: 2018 FULPHILA ® (pegfilgrastim-jmdb) is biosimilar* to NEULASTA ® (pegfilgrastim). (1) | Biocon Biologics Inc. | Biocon Biologics Limited |